U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C40H52O4
Molecular Weight 596.8385
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 9
Charge 0

SHOW SMILES / InChI
Structure of ASTAXANTHIN

SMILES

CC(\C=C\C=C(C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)[C@@H](O)CC2(C)C

InChI

InChIKey=MQZIGYBFDRPAKN-UWFIBFSHSA-N
InChI=1S/C40H52O4/c1-27(17-13-19-29(3)21-23-33-31(5)37(43)35(41)25-39(33,7)8)15-11-12-16-28(2)18-14-20-30(4)22-24-34-32(6)38(44)36(42)26-40(34,9)10/h11-24,35-36,41-42H,25-26H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,27-15+,28-16+,29-19+,30-20+/t35-,36-/m0/s1

HIDE SMILES / InChI
Molecular Formula C40H52O4
Molecular Weight 596.8385
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 9
Optical Activity UNSPECIFIED

Description

Astaxanthin (ATX), a red-orange carotenoid that originates the pink or red color of salmon, trout, lobster, shrimp, and other sea organisms, exhibits antioxidant, anti-inflammatory, and antiapoptotic effects. Recently, ATX was shown to protect neurons in experimental models of acute injuries, chronic neurodegenerative disorders, and neurological diseases and was proposed as a beneficial strategy to treat neurological diseases. In addition, ATX chelates several metal ions, preventing metal ion-induced oxidative stress, it has anti-inflammatory properties and it acts as a damper of singlet oxygen levels. Being a part of naturally derived supplements Oncotris™ in genitourinary cancer patients was revealed, that astaxanthin could support the body to overcome the treatment-related toxicities - and the relative oxidative stress in cancer patients.

CNS Activity

Originator

Approval Year

2010
465
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Basic research
Unknown

Approved Use

Unknown
Preventing
Basic research
Unknown

Approved Use

Unknown
Preventing
Not Provided
504
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Patents

JP2000050884A
2
JP2000060532A
1
JP2000080073A
2
JP2000086521A
1
JP2000189102A
1
JP2000262294A
1
JP2001002569A
1
JP2001061466A
1
JP2001095500A
1
JP2001114673A
1
JP2001114674A
1
JP2001114683A
1
JP2001190294A
1
JP2001211781A
1
JP2001352995A
3
JP2002017295A
1
JP2002058433A
1
JP2002080351A
1
JP2002159279A
1
JP2002218940A
4
JP2002226367A
1
JP2002226368A
1
JP2002233331A
1
JP2002253266A
1
JP2002348275A
1
JP2002348276A
1
JP2003064360A
1
JP2003088329A
1
JP2003189846A
1
JP2003219808A
1
JP2003238442A
1
JP2003238524A
1
JP2003286251A
1
JP2003319795A
1
JP2003335668A
1
JP2003510353A
1
JP2003511051A
1
JP2004024060A
1
JP2004033062A
1
JP2004033070A
1
JP2004041147A
1
JP2004089015A
1
JP2004129504A
1
JP2004154055A
1
JP2004208504A
1
JP2004210725A
1
JP2004217933A
3
JP2004292461A
1
JP2004331512A
1
JP2005002175A
1
JP2005021098A
1

Sample Use Guides

In Vivo Use Guide
astaxanthin (Oncotris™) used as supplementary management in genitourinary cancer patients who had undergone oncological therapy
Route of Administration: Oral
In Vitro Use Guide
There were investigated whether the antioxidant agent astaxanthin (ATX) protects neurons from AβOs-induced excessive mitochondrial ROS generation, NFATc4 activation, and RyR2 mRNA downregulation. Primary hippocampal cultures were incubated with 0.1 μM ATX for 1.5 h prior to AβOs addition (500 nM). It was found that incubation with ATX (≤10 μM) for ≤24 h was nontoxic to neurons, evaluated by the live/dead assay. Preincubation with 0.1 μM ATX also prevented the neuronal mitochondrial H2O2 generation induced within minutes of AβOs addition. Longer exposures to AβOs (6 h) promoted NFATc4-eGFP nuclear translocation and decreased RyR2 mRNA levels, evaluated by detection of the eGFP-tagged fluorescent plasmid and qPCR, respectively. Preincubation with 0.1 μM ATX prevented both effects. These results indicate that ATX protects neurons from the noxious effects of AβOs on mitochondrial ROS production, NFATc4 activation, and RyR2 gene expression downregulation.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:37:01 UTC 2023
Edited
by admin
on Fri Dec 15 17:37:01 UTC 2023
Record UNII
8XPW32PR7I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ASTAXANTHIN
HSDB   INCI   MART.   MI   VANDF   WHO-DD  
INCI  
Official Name English
ASTAXANTHIN [HSDB]
Common Name English
ASTAXANTHIN [INCI]
Common Name English
BIOASTIN
Brand Name English
.BETA.,.BETA.-CAROTENE-4,4'-DIONE, 3,3'-DIHYDROXY-, (3S,3'S)-
Common Name English
3,3'-DIHYDROXY-4,4'-DIKETO-.BETA.-CAROTENE
Common Name English
Astaxanthin [WHO-DD]
Common Name English
ASTAXANTHIN (CONSTITUENT OF ASTAXANTHIN ESTERS) [DSC]
Common Name English
ASTAXANTHIN [MART.]
Common Name English
ALL-TRANS-ASTAXANTHIN
Common Name English
ASTAREAL
Brand Name English
(3S,3'S)-3,3'-DIHYDROXY-.BETA.,.BETA.-CAROTENE-4,4'-DIONE
Common Name English
ASTAXANTHIN [VANDF]
Common Name English
ASTAXANTHIN [USP-RS]
Common Name English
ASTAXANTHIN [MI]
Common Name English
OVOESTER
Common Name English
NSC-635689
Code English
Classification Tree Code System Code
NCI_THESAURUS C68309
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
NCI_THESAURUS C210
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
DSLD 12 (Number of products:746)
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
Code System Code Type Description
ECHA (EC/EINECS)
207-451-4
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
DRUG BANK
DB06543
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
EVMPD
SUB21932
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
EPA CompTox
DTXSID00893777
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
SMS_ID
100000091870
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
CAS
472-61-7
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
NCI_THESAURUS
C63653
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
MERCK INDEX
m2115
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY Merck Index
MESH
C005948
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
HSDB
7468
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
CHEBI
40968
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
DAILYMED
8XPW32PR7I
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
NSC
635689
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
RXCUI
18451
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY RxNorm
RS_ITEM_NUM
1044200
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
PUBCHEM
5281224
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
FDA UNII
8XPW32PR7I
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
WIKIPEDIA
ASTAXANTHIN
Created by admin on Fri Dec 15 17:37:01 UTC 2023 , Edited by admin on Fri Dec 15 17:37:01 UTC 2023
PRIMARY
Related Record Type Details
SPIRULINA
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT
Unit: ng/g; The content of carotenoids from selected commercially available health supplements (Spirulina)
ASSAY (HPLC)
Batch Data
Related Record Type Details
Structure of ASTAXANTHIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966